Cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. As a consequence, interactions with cardiovascular disease specialists have intensified to the point of the development of a new discipline termed cardio-oncology. As an additional consequence, so-called cardio-oncology clinics have emerged, in most cases staffed by cardiologists with an interest in the field. This article addresses this gap and summarizes key points in the development of a cardio-oncology clinic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hfc.2016.12.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility, Acceptability, and Preliminary Efficacy of the Taking Care of Us Intervention for Couples Living With Heart Failure.
Innov Aging
December 2024
William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
Background And Objectives: Despite the significant impact of heart failure on both members of the care dyad, few interventions focus on optimizing the health of the dyad. The current study examined the feasibility and acceptability of the novel Taking Care of Us (TCU) program with mid-late-life couples living with heart failure and explored preliminary efficacy.
Research Design And Methods: This NIH Stage I study used a 2-arm randomized controlled trial with pretest-post-test design and an additional 5-month follow-up to compare TCU with an educational counseling attention-control condition.
Cardiovascular Disease and Cancer: A Dangerous Liaison.
Arterioscler Thromb Vasc Biol
January 2025
Cardiovascular Research Center, New York University Langone Health, New York University Grossman School of Medicine. (A.A.C.N., J.M.D., K.J.M.).
The field of cardio-oncology has traditionally focused on the impact of cancer and its therapies on cardiovascular health. Mounting clinical and preclinical evidence, however, indicates that the reverse may also be true: cardiovascular disease can itself influence tumor growth and metastasis. Numerous epidemiological studies have reported that individuals with prevalent cardiovascular disease have an increased incidence of cancer.
View Article and Find Full Text PDFTrends and disparities in cardiovascular disease-related mortality among adults with myeloproliferative neoplasms in USA.
Eur Heart J Open
January 2025
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 63117, USA.
Aims: We aimed to perform a retrospective cohort study using the Centers for Disease Control and Prevention's (CDC's) Wide-Ranging Online Data for Epidemiologic Research (WONDER) database to analyse the trends in cardiovascular disease (CVD)-related mortality in patients with myeloproliferative neoplasms (MPNs) from 1999 to 2020.
Methods And Results: We analysed the death certificate data from the CDC WONDER database from 1999 to 2020 for CVD with co-morbid myeloproliferative disorders in the US population. Age-adjusted mortality rates (AAMRs) and 95% confidence intervals (CIs) were computed per 1 million population by standardizing crude mortality rates to the 2000 US census population.
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?
ESC Heart Fail
January 2025
Cardiology Unit, University Hospital 'Paolo Giaccone', Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy.
Aims: Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.
Methods: The study population consisted of 148 patients (45% women, mean age: 58 ± 14.
Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function.
Cardiooncology
January 2025
Division of Cardiology, Tel Aviv Sourasky medical Center, Tel Aviv, Israel.
Aims: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) events. While pre-treatment reduced left ventricular ejection fraction (LVEF) is considered a marker for high-risk cardiotoxicity and a contraindication for anthracycline and HER2-targeted therapies, there is limited evidence on the safety and efficacy of ICIs therapy in patients presenting with pre-treatment reduced LVEF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!